GlassScriptPhysician profile
Joseph A Gordon
NPI 1811243652
$14,167.57
in general payments reported to CMS, 2019-2025
39 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $433 · 2021: $543 · 2022: $1,117 · 2023: $7,505 · 2024: $1,554 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,021 · Food and Beverage: $4,330 · Travel and Lodging: $264 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,021.10 |
| Food and Beverage | $4,329.77 |
| Travel and Lodging | $264.13 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,348.41 | 2023-2024 | Da Vinci Surgical System, Ion |
| Glaxosmithkline, LLC. | $1,416.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $813.68 | 2021-2025 | Dupixent |
| Covidien LP | $793.65 | 2019 | |
| Merck Sharp & Dohme LLC | $609.78 | 2019-2025 | Winrevair, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.85 | 2020-2025 | Ofev, Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $472.99 | 2019-2024 | |
| United Therapeutics Corporation | $465.81 | 2020-2025 | Tyvaso, Tyvaso, Orenitram |
| Grifols USA, LLC | $310.89 | 2020-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $251.17 | 2021-2025 | Uptravi, Opsumit |
| Genzyme Corporation | $215.73 | 2022-2025 | |
| Olympus America INC. | $215.01 | 2021-2023 | Spiration Valve System |
| Abbvie INC. | $206.63 | 2022-2025 | |
| Verona Pharma, INC. | $174.91 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $147.33 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $145.65 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Insmed, INC. | $107.95 | 2020-2025 | Arikayce |
| Shionogi INC | $88.22 | 2022-2023 | Fetroja |
| Gilead Sciences, INC. | $76.16 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $75.88 | 2022-2023 | Acthar |
| Sanofi-Aventis U.S. LLC | $72.50 | 2019 | |
| Lilly USA, LLC | $71.48 | 2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $69.82 | 2019-2022 | |
| Mylan Specialty L.P. | $59.34 | 2023-2024 | Yupelri |
| Advanced Respiratory, INC | $46.62 | 2020-2021 | |
| Harmony Biosciences LLC | $42.52 | 2022 | |
| Genentech USA, INC. | $42.16 | 2019-2020 | |
| Ethicon INC. | $39.02 | 2021 | |
| Amgen INC. | $33.25 | 2023-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $31.72 | 2023 | Xywav |
| Viatris Specialty LLC | $31.24 | 2025 | Yupelri |
| Chiesi USA, INC. | $29.52 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.34 | 2023 | |
| Electromed, INC. | $23.74 | 2025 | Smartvest |
| E.R. Squibb & Sons, L.L.C. | $19.95 | 2021 | |
| Pfizer INC. | $18.12 | 2024 | |
| Philips North America LLC | $17.96 | 2024 | (8874) Incourage |
| Mayne Pharma Commercial LLC | $17.30 | 2020 | |
| Circassia INC. | $14.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.